XHKG
2162
Market cap1.63bUSD
Jun 16, Last price
46.50HKD
1D
-2.11%
1Q
23.34%
IPO
-33.00%
Name
KeyMed Biosciences Inc
Chart & Performance
P/E
—
P/S
27.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.68%
Rev. gr., 5y
%
Revenues
428m
+20.91%
Net income
-515m
L+43.38%
CFO
0k
P
Earnings
Jun 25, 2025
Profile
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 428,124 20.91% | 354,095 253.87% | 100,063 -9.26% | |||
Cost of revenue | 1,046,222 | 810,166 | 643,871 | |||
Unusual Expense (Income) | ||||||
NOPBT | (618,098) | (456,071) | (543,808) | |||
NOPBT Margin | ||||||
Operating Taxes | 6,260 | 1,597 | 4,518 | |||
Tax Rate | ||||||
NOPAT | (624,358) | (457,668) | (548,326) | |||
Net income | (515,241) 43.38% | (359,357) 16.63% | (308,115) -92.10% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (32,901) | (51,135) | ||||
BB yield | 0.26% | 0.38% | ||||
| Debt | ||||||
Debt current | 484,735 | 65,252 | 72,241 | |||
Long-term debt | 292,182 | 394,507 | 81,734 | |||
Deferred revenue | 228,194 | 163,671 | ||||
Other long-term liabilities | 275,125 | (28,800) | ||||
Net debt | (1,588,720) | (2,281,057) | (470,666) | |||
| Cash flow | ||||||
Cash from operating activities | (303,620) | (401,934) | ||||
CAPEX | (327,194) | (279,549) | ||||
Cash from investing activities | 468,203 | (645,586) | ||||
Cash from financing activities | 72,131 | (8,059) | ||||
FCF | (826,149) | (702,399) | (885,911) | |||
| Balance | ||||||
Cash | 2,155,612 | 2,719,186 | 3,175,326 | |||
Long term investments | 210,025 | 21,630 | (2,550,685) | |||
Excess cash | 2,344,231 | 2,723,111 | 619,638 | |||
Stockholders' equity | 2,475,215 | (5,496,930) | (5,145,935) | |||
Invested Capital | 1,159,344 | 9,130,646 | 8,740,967 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 261,947 | 261,368 | 261,127 | |||
Price | 30.90 -37.07% | 49.10 -3.73% | 51.00 60.38% | |||
Market cap | 8,094,162 -36.93% | 12,833,148 -3.64% | 13,317,454 160.36% | |||
EV | 6,506,083 | 10,552,593 | 12,845,718 | |||
EBITDA | (618,098) | (386,910) | (507,685) | |||
EV/EBITDA | ||||||
Interest | 17,259 | 8,219 | ||||
Interest/NOPBT | ||||||